vida: extract claims from 2026-01-29-cdc-nchs-us-life-expectancy-2024-record-high

- Source: inbox/queue/2026-01-29-cdc-nchs-us-life-expectancy-2024-record-high.md
- Domain: health
- Claims: 1, Entities: 0
- Enrichments: 3
- Extracted by: pipeline ingest (OpenRouter anthropic/claude-sonnet-4.5)

Pentagon-Agent: Vida <PIPELINE>

domains/health/cvd-stagnation-drives-us-life-expectancy-plateau-3-11x-more-than-drug-deaths.md

@@ -10,12 +10,17 @@ agent: vida
 scope: causal
 sourcer: Shiels MS, Chernyavskiy P, Anderson WF, et al. (NCI)
 related_claims: ["[[Americas declining life expectancy is driven by deaths of despair concentrated in populations and regions most damaged by economic restructuring since the 1980s]]", "[[Big Food companies engineer addictive products by hacking evolutionary reward pathways creating a noncommunicable disease epidemic more deadly than the famines specialization eliminated]]"]
-supports:
-- Midlife CVD mortality (ages 40-64) increased in many US states after 2010 representing a reversal not merely stagnation
-reweave_edges:
-- Midlife CVD mortality (ages 40-64) increased in many US states after 2010 representing a reversal not merely stagnation|supports|2026-04-07
+supports: ["Midlife CVD mortality (ages 40-64) increased in many US states after 2010 representing a reversal not merely stagnation"]
+reweave_edges: ["Midlife CVD mortality (ages 40-64) increased in many US states after 2010 representing a reversal not merely stagnation|supports|2026-04-07"]
+related: ["cvd-stagnation-drives-us-life-expectancy-plateau-3-11x-more-than-drug-deaths", "cvd-stagnation-reversed-racial-health-convergence-by-stopping-black-mortality-improvements", "midlife-cvd-mortality-increased-in-many-us-states-after-2010-representing-reversal-not-stagnation"]
 ---
 
 # CVD mortality stagnation drives US life expectancy plateau 3-11x more than drug deaths inverting the dominant opioid crisis narrative
 
-NCI researchers quantified the contribution of different mortality causes to US life expectancy stagnation between 2010 and 2017. CVD stagnation held back life expectancy at age 25 by 1.14 years in both women and men. Rising drug-related deaths had a much smaller effect: 0.1 years in women and 0.4 years in men. This creates a ratio where CVD stagnation effect is approximately 3-11x larger than drug mortality effect. The authors concluded that stagnating decline in CVD mortality was 'the main culprit outpacing and overshadowing the effects of all other causes of death.' This directly contradicts the dominant public narrative attributing US mortality stagnation primarily to the opioid epidemic. The finding is particularly significant because CVD/metabolic decline is structural and not easily reversible like epidemic-driven mortality, suggesting the life expectancy plateau represents a deeper health system failure than crisis-driven explanations imply. This mechanism was visible in 2020 data and has been confirmed by subsequent 2025-2026 literature including cohort-level analysis showing a distinct 2010 period effect.
+NCI researchers quantified the contribution of different mortality causes to US life expectancy stagnation between 2010 and 2017. CVD stagnation held back life expectancy at age 25 by 1.14 years in both women and men. Rising drug-related deaths had a much smaller effect: 0.1 years in women and 0.4 years in men. This creates a ratio where CVD stagnation effect is approximately 3-11x larger than drug mortality effect. The authors concluded that stagnating decline in CVD mortality was 'the main culprit outpacing and overshadowing the effects of all other causes of death.' This directly contradicts the dominant public narrative attributing US mortality stagnation primarily to the opioid epidemic. The finding is particularly significant because CVD/metabolic decline is structural and not easily reversible like epidemic-driven mortality, suggesting the life expectancy plateau represents a deeper health system failure than crisis-driven explanations imply. This mechanism was visible in 2020 data and has been confirmed by subsequent 2025-2026 literature including cohort-level analysis showing a distinct 2010 period effect.
+
+## Extending Evidence
+
+**Source:** CDC NCHS Data Brief 548, January 2026
+
+The 2024 life expectancy improvement was driven by both declining drug deaths (-26.2%) AND declining heart disease mortality, suggesting CVD improvements contributed alongside overdose reductions. This complicates the '3-11x more important' framing, as both acute and chronic causes moved favorably in 2024.

domains/health/us-life-expectancy-2024-recovery-reflects-acute-mortality-improvement-not-structural-reversal.md

@@ -0,0 +1,20 @@
+---
+type: claim
+domain: health
+description: "The 2024 life expectancy record (79.0 years) was driven by a 26.2% decline in drug overdoses and reduced unintentional injury deaths, but obesity remains at 40.3% and IHME projects US falling to 66th globally by 2050 due to chronic metabolic disease"
+confidence: likely
+source: CDC NCHS Data Brief 548 and 549, January 2026
+created: 2026-05-10
+title: US life expectancy recovery to all-time high in 2024 reflects acute mortality improvement that leaves structural metabolic threats intact
+agent: vida
+sourced_from: health/2026-01-29-cdc-nchs-us-life-expectancy-2024-record-high.md
+scope: structural
+sourcer: CDC NCHS
+supports: ["us-life-expectancy-projected-stall-2050-obesity-drug-mortality-offset-cvd-gains"]
+challenges: ["americas-declining-life-expectancy-is-driven-by-deaths-of-despair-concentrated-in-populations-and-regions-most-damaged-by-economic-restructuring-since-the-1980s"]
+related: ["americas-declining-life-expectancy-is-driven-by-deaths-of-despair-concentrated-in-populations-and-regions-most-damaged-by-economic-restructuring-since-the-1980s", "us-life-expectancy-projected-stall-2050-obesity-drug-mortality-offset-cvd-gains", "us-healthspan-declining-while-lifespan-recovers-creating-divergence", "cvd-stagnation-drives-us-life-expectancy-plateau-3-11x-more-than-drug-deaths"]
+---
+
+# US life expectancy recovery to all-time high in 2024 reflects acute mortality improvement that leaves structural metabolic threats intact
+
+CDC NCHS reports US life expectancy reached an all-time high of 79.0 years in 2024, surpassing the pre-COVID 2019 level of 78.8 years. The primary driver was a 26.2% year-over-year decline in drug overdose deaths (from 31.3 to 23.1 per 100K), with synthetic opioid deaths falling 35.6%. This represents the largest single-year improvement in US drug overdose history. However, this acute mortality improvement does not address the structural metabolic disease burden that drives long-term projections. Obesity prevalence remains at 40.3% nationally, and IHME forecasts project the US falling from current rankings to 66th globally in life expectancy by 2050 due to compounding metabolic disease. The 2024 recovery demonstrates that the 'deaths of despair' crisis (2017-2022) was partially cyclical and responsive to intervention (naloxone distribution, fentanyl supply disruption, treatment expansion), but the underlying structural determinants identified in existing KB claims—economic restructuring, social isolation, ultra-processed food environments—remain unaddressed. The improvement in acute causes (overdoses, homicides) coexists with persistent chronic disease trajectories that will dominate future mortality patterns.

domains/health/us-life-expectancy-projected-stall-2050-obesity-drug-mortality-offset-cvd-gains.md

@@ -23,3 +23,10 @@ The structural threats offsetting these gains are obesity and drug mortality. IH
 This forecast provides critical context for the 2024 CDC life expectancy all-time high of 79.0 years. The IHME model treats the 2024 improvement as partially cyclical (COVID dissipation plus fentanyl supply disruption) rather than structural resolution. The divergence between acute mortality improvement (CDC 2024) and structural disease burden trajectory (IHME 2050) suggests the binding constraints on US healthspan remain obesity-driven metabolic disease and socioeconomic drivers of drug mortality, even as acute cardiovascular care improves.
 
 The global ranking decline is particularly revealing: it indicates the US is not declining absolutely but failing to address structural risk factors as effectively as peer nations. The 2050 projection assumes current policy trajectories continue—it does not account for potential GLP-1 scale effects, major policy reforms, or fentanyl supply dynamics that could alter the trajectory.
+
+
+## Supporting Evidence
+
+**Source:** CDC NCHS Data Brief 548 and 549, January 2026
+
+The 2024 life expectancy recovery to 79.0 years was driven by acute mortality improvements (drug overdoses -26.2%, unintentional injuries -14%, homicides declining), validating the 'drug mortality offset' mechanism. However, obesity prevalence remains at 40.3% and chronic metabolic disease trajectories are unchanged, supporting the projection that structural metabolic threats will dominate post-2024 mortality patterns.

inbox/archive/health/2026-01-29-cdc-nchs-us-life-expectancy-2024-record-high.md

@@ -7,10 +7,13 @@ date: 2026-01-29
 domain: health
 secondary_domains: []
 format: government-report
-status: unprocessed
+status: processed
+processed_by: vida
+processed_date: 2026-05-10
 priority: high
 tags: [life-expectancy, deaths-of-despair, drug-overdose, mortality, epidemiology, population-health, CDC, NCHS]
 intake_tier: research-task
+extraction_model: "anthropic/claude-sonnet-4.5"
 ---
 
 ## Content